Tags

Type your tag names separated by a space and hit enter

Favorable prognosis in colorectal cancer patients with co-expression of c-MYC and β-catenin.
BMC Cancer. 2016 09 13; 16(1):730.BC

Abstract

BACKGROUND

The purpose of our research was to determine the prognostic impact and clinicopathological feature of c-MYC and β-catenin overexpression in colorectal cancer (CRC) patients.

METHODS

Using immunohistochemistry (IHC), we measured the c-MYC and β-catenin expression in 367 consecutive CRC patients retrospectively (cohort 1). Also, c-MYC expression was measured by mRNA in situ hybridization. Moreover, to analyze regional heterogeneity, three sites of CRC including the primary, distant and lymph node metastasis were evaluated in 176 advanced CRC patients (cohort 2).

RESULTS

In cohort 1, c-MYC protein and mRNA overexpression and β-catenin nuclear expression were found in 201 (54.8 %), 241 (65.7 %) and 221 (60.2 %) of 367 patients, respectively, each of which was associated with improved prognosis (P = 0.011, P = 0.012 and P = 0.033, respectively). Moreover, co-expression of c-MYC and β-catenin was significantly correlated with longer survival by univariate (P = 0.012) and multivariate (P = 0.048) studies. Overexpression of c-MYC protein was associated with mRNA overexpression (ρ, 0.479; P < 0.001) and nuclear β-catenin expression (ρ, 0.282; P < 0.001). Expression of c-MYC and β-catenin was heterogeneous depending on location in advanced CRC patients (cohort 2). Nevertheless, both c-MYC and β-catenin expression in primary cancer were significantly correlated with improved survival in univariate (P = 0.001) and multivariate (P = 0.002) analyses. c-MYC and β-catenin expression of lymph node or distant metastatic tumor was not significantly correlated with patients' prognosis (P > 0.05).

CONCLUSIONS

Co-expression of c-MYC and β-catenin was independently correlated with favorable prognosis in CRC patient. We concluded that the expression of c-MYC and β-catenin might be useful predicting indicator of CRC patient's prognosis.

Authors+Show Affiliations

Department of Pathology, Seoul National University Bundang Hospital, 173-82 Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-707, Republic of Korea.Department of Pathology, Seoul National University Bundang Hospital, 173-82 Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-707, Republic of Korea. Department of Pathology, Seoul National University College of Medicine, 103 Daehak-ro (Yongon-dong), Jongno-gu, Seoul, 110-799, Republic of Korea.Department of Pathology, Haeundae Paik Hospital, Inje University College of Medicine, 875, Haeun-daero, Haeundae-gu, Busan, 612-896, Republic of Korea.Department of Surgery, Seoul National University Bundang Hospital, 173-82 Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-707, Republic of Korea.Department of Surgery, Seoul National University Bundang Hospital, 173-82 Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-707, Republic of Korea.Department of Pathology, Seoul National University Bundang Hospital, 173-82 Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-707, Republic of Korea. Department of Pathology, Seoul National University College of Medicine, 103 Daehak-ro (Yongon-dong), Jongno-gu, Seoul, 110-799, Republic of Korea.Department of Pathology, Seoul National University College of Medicine, 103 Daehak-ro (Yongon-dong), Jongno-gu, Seoul, 110-799, Republic of Korea.Department of Pathology, Seoul National University Bundang Hospital, 173-82 Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-707, Republic of Korea. hye2@snu.ac.kr.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

27619912

Citation

Lee, Kyu Sang, et al. "Favorable Prognosis in Colorectal Cancer Patients With Co-expression of c-MYC and SS-catenin." BMC Cancer, vol. 16, no. 1, 2016, p. 730.
Lee KS, Kwak Y, Nam KH, et al. Favorable prognosis in colorectal cancer patients with co-expression of c-MYC and β-catenin. BMC Cancer. 2016;16(1):730.
Lee, K. S., Kwak, Y., Nam, K. H., Kim, D. W., Kang, S. B., Choe, G., Kim, W. H., & Lee, H. S. (2016). Favorable prognosis in colorectal cancer patients with co-expression of c-MYC and β-catenin. BMC Cancer, 16(1), 730. https://doi.org/10.1186/s12885-016-2770-7
Lee KS, et al. Favorable Prognosis in Colorectal Cancer Patients With Co-expression of c-MYC and SS-catenin. BMC Cancer. 2016 09 13;16(1):730. PubMed PMID: 27619912.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Favorable prognosis in colorectal cancer patients with co-expression of c-MYC and β-catenin. AU - Lee,Kyu Sang, AU - Kwak,Yoonjin, AU - Nam,Kyung Han, AU - Kim,Duck-Woo, AU - Kang,Sung-Bum, AU - Choe,Gheeyoung, AU - Kim,Woo Ho, AU - Lee,Hye Seung, Y1 - 2016/09/13/ PY - 2015/07/12/received PY - 2016/09/06/accepted PY - 2016/9/14/entrez PY - 2016/9/14/pubmed PY - 2017/9/7/medline KW - Colorectal cancer KW - Immunohistochemistry KW - Prognosis KW - c-MYC KW - mRNA in situ hybridization KW - β-catenin SP - 730 EP - 730 JF - BMC cancer JO - BMC Cancer VL - 16 IS - 1 N2 - BACKGROUND: The purpose of our research was to determine the prognostic impact and clinicopathological feature of c-MYC and β-catenin overexpression in colorectal cancer (CRC) patients. METHODS: Using immunohistochemistry (IHC), we measured the c-MYC and β-catenin expression in 367 consecutive CRC patients retrospectively (cohort 1). Also, c-MYC expression was measured by mRNA in situ hybridization. Moreover, to analyze regional heterogeneity, three sites of CRC including the primary, distant and lymph node metastasis were evaluated in 176 advanced CRC patients (cohort 2). RESULTS: In cohort 1, c-MYC protein and mRNA overexpression and β-catenin nuclear expression were found in 201 (54.8 %), 241 (65.7 %) and 221 (60.2 %) of 367 patients, respectively, each of which was associated with improved prognosis (P = 0.011, P = 0.012 and P = 0.033, respectively). Moreover, co-expression of c-MYC and β-catenin was significantly correlated with longer survival by univariate (P = 0.012) and multivariate (P = 0.048) studies. Overexpression of c-MYC protein was associated with mRNA overexpression (ρ, 0.479; P < 0.001) and nuclear β-catenin expression (ρ, 0.282; P < 0.001). Expression of c-MYC and β-catenin was heterogeneous depending on location in advanced CRC patients (cohort 2). Nevertheless, both c-MYC and β-catenin expression in primary cancer were significantly correlated with improved survival in univariate (P = 0.001) and multivariate (P = 0.002) analyses. c-MYC and β-catenin expression of lymph node or distant metastatic tumor was not significantly correlated with patients' prognosis (P > 0.05). CONCLUSIONS: Co-expression of c-MYC and β-catenin was independently correlated with favorable prognosis in CRC patient. We concluded that the expression of c-MYC and β-catenin might be useful predicting indicator of CRC patient's prognosis. SN - 1471-2407 UR - https://www.unboundmedicine.com/medline/citation/27619912/Favorable_prognosis_in_colorectal_cancer_patients_with_co_expression_of_c_MYC_and_β_catenin_ L2 - https://bmccancer.biomedcentral.com/articles/10.1186/s12885-016-2770-7 DB - PRIME DP - Unbound Medicine ER -